INNODIA

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes

INNODIA assembles a comprehensive, complementary consortium of leading clinicians overseeing T1D registries and large clinical trial centres, aligned with basic science experts in beta-cell pathophysiology, immunology, biomarker discovery, bioinformatics, systems biology and trial design. INNODIA will accelerate understanding of T1D via coordinated studies of unique clinical samples and translation-oriented preclinical models delivering novel biomarkers and interventions for testing. Participants will be consented to recall, creating a ‘living biobank’.  

In Norway we recruite first degree family members (aged 5-40 years) of patients with type 1 diabetes. First a blood test of autoantibodies is peformed and if positive prediabetes is diagnosed with a high risk for developing clinical type 1 diabetes. These participants undergo an organized follow-up and may be eligble for studies aiming to prevent clinical type 1 diabetes. Such prevention studies will start recruiting participants in the two years to come. Newly diagnosed patients are now enrolled in the DiViDInt Trial, which is affiliated to INNODIA.

READ MORE

Primary investigators:
Knut Dahl-Jørgensen
Torild Skrivarhaug
Geir Joner
Lars Krogvold

Co-investigators/participants:
Kristin Namtvedt Tuv, Consultant pediatrician, Sørlandet Hospital, Norway
Camilla Steinhovden, Study Nurse, Pediatric Dept. Oslo University Hospital

External collaborators:
INNODIA is a EU-IMI2-consortium with 40 partners: 31 academic institutions and clinics, 6 industrial partners and 2 patient organizations and one SME.

In fall 2020, 4 INNODIA clinical trials are launched and planned to be completed by 2022: MELD-ATG, IMPACT, VeR-A-T1D, CFZ533. The goal is to protect and strengthen the insulin producing beta cell in the pancreas. INNODIA is determined to find a way to stop the body´s immune attack from further destroying beta cells in newly diagnosed people with type one diabetes.

See www.innodia.eu